Epigenetic mechanisms as a new approach in cancer treatment: An updated review

Genes and Diseases

Volumn 5, Issue 4, 2018, Pages 304-311

  Fardi, Masoumeh ^a,b   Solali, Saeed ^b,c   Farshdousti Hagh, Majid ^d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer; Epigenetic; Mechanisms; Methylation; Treatment

Indexed keywords

DNA METHYLTRANSFERASE; MICRORNA; UNTRANSLATED RNA;

CANCER GROWTH; CANCER THERAPY; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENETIC VARIATION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; MALIGNANT NEOPLASM; NUCLEOSOME; REVIEW;

EID: 85049345620     PISSN: 23524820     EISSN: 23523042     Source Type: Journal    
DOI: 10.1016/j.gendis.2018.06.003     Document Type: Review

References (74)

1. Dupont, C., Armant, D.R., Brenner, C.A., Epigenetics: definition, mechanisms and clinical perspective. Semin Reprod Med 27:5 (2009), 351–357.
2. Kelly, T.K., De Carvalho, D.D., Jones, P.A., Epigenetic modifications as therapeutic targets. Nat Biotechnol 28:10 (2010), 1069–1078.
3. Walter, M.J., Ding, L., Shen, D., et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25:7 (2011), 1153–1158.
4. Stegelmann, F., Bullinger, L., Schlenk, R.F., et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 25:7 (2011), 1217–1219.
5. Fong, C.Y., Morison, J., Dawson, M.A., Epigenetics in the hematologic malignancies. Haematologica 99:12 (2014), 1772–1783.
6. Cutter, A.R., Hayes, J.J., A brief review of nucleosome structure. FEBS Lett 589:20 Pt A (2015), 2914–2922.
7. Luger, K., Mader, A.W., Richmond, R.K., Sargent, D.F., Richmond, T.J., Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389:6648 (1997), 251–260.
8. Jones, P.A., Baylin, S.B., The epigenomics of cancer. Cell 128:4 (2007), 683–692.
9. Villeneuve, L.M., Natarajan, R., The role of epigenetics in the pathology of diabetic complications. Am J Physiol Ren Physiol 299:1 (2010), F14–F25.
10. Javierre, B.M., Fernandez, A.F., Richter, J., et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res 20:2 (2010), 170–179.
11. Adcock, I.M., Ito, K., Barnes, P.J., Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD 2:4 (2005), 445–455.
12. Egger, G., Liang, G., Aparicio, A., Jones, P.A., Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:6990 (2004), 457–463.
13. Feinberg, A.P., Vogelstein, B., Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301:5895 (1983), 89–92.
14. Eden, A., Gaudet, F., Waghmare, A., Jaenisch, R., Chromosomal instability and tumors promoted by DNA hypomethylation. Science (New York, NY), 300(5618), 2003, 455.
15. Esteller, M., Corn, P.G., Baylin, S.B., Herman, J.G., A gene hypermethylation profile of human cancer. Cancer Res 61:8 (2001), 3225–3229.
16. Shen, L., Toyota, M., Kondo, Y., et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 104:47 (2007), 18654–18659.
17. Figueroa, M.E., Lugthart, S., Li, Y., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17:1 (2010), 13–27.
18. Ellinger, J., Kahl, P., von der Gathen, J., et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate 70:1 (2010), 61–69.
19. Bachmann, I.M., Halvorsen, O.J., Collett, K., et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol – Offic J Am Soc Clin Oncol 24:2 (2006), 268–273.
20. Weller, M., Stupp, R., Reifenberger, G., et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat Rev Neurol 6:1 (2010), 39–51.
21. Kanai, Y., Genome-wide DNA methylation profiles in precancerous conditions and cancers. Cancer Sci 101:1 (2010), 36–45.
22. Kondo, T., Oka, T., Sato, H., et al. Accumulation of aberrant CpG hypermethylation by Helicobacter pylori infection promotes development and progression of gastric MALT lymphoma. Int J Oncol 35:3 (2009), 547–557.
23. Shen, L., Kondo, Y., Ahmed, S., et al. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res 67:23 (2007), 11335–11343.
24. Ibanez de Caceres, I., Cortes-Sempere, M., Moratilla, C., et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene 29:11 (2010), 1681–1690.
25. Voso, M.T., Santini, V., Finelli, C., et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res – Offic J Am Assoc Cancer Res 15:15 (2009), 5002–5007.
26. Martens, J.W., Margossian, A.L., Schmitt, M., Foekens, J., Harbeck, N., DNA methylation as a biomarker in breast cancer. Future Oncol (London, England) 5:8 (2009), 1245–1256.
27. Jarmalaite, S., Andrekute, R., Scesnaite, A., Suziedelis, K., Husgafvel-Pursiainen, K., Jankevicius, F., Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study. J Cancer Res Clin Oncol 136:6 (2010), 847–854.
28. Comoglio, P.M., Giordano, S., Trusolino, L., Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:6 (2008), 504–516.
29. Robertson, K.D., DNA methylation and human disease. Nat Rev Genet 6:8 (2005), 597–610.
30. Lister, R., Pelizzola, M., Dowen, R.H., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462:7271 (2009), 315–322.
31. Cheng, X., Blumenthal, R.M., Mammalian DNA methyltransferases: a structural perspective. Structure (London, England: 1993) 16:3 (2008), 341–350.
32. Watt, F., Molloy, P.L., Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Gene Dev 2:9 (1988), 1136–1143.
33. Ghavifekr Fakhr, M., Farshdousti Hagh, M., Shanehbandi, D., Baradaran, B., DNA methylation pattern as important epigenetic criterion in cancer. Genet Res Int, 2013, 2013, 9.
34. Zare, M., Bastami, M., Solali, S., Alivand, M.R., Aberrant miRNA promoter methylation and EMT-involving miRNAs in breast cancer metastasis: diagnosis and therapeutic implications. J Cell Physiol 233:5 (2018), 3729–3744.
35. Rahmani, M., Talebi, M., Farshdousti Hagh, M., Hosseinpour Feizi, A.A., Solali, S., Aberrant DNA methylation of key genes and acute lymphoblastic leukemia. Biomed Pharmacother 97 (2018), 1493–1500.
36. Gonzalo, S., Blasco, M.A., Role of Rb family in the epigenetic definition of chromatin. Cell Cycle (Georgetown, Tex) 4:6 (2005), 752–755.
37. Gros, C., Fahy, J., Halby, L., et al. DNA methylation inhibitors in cancer: recent and future approaches. Biochimie 94:11 (2012), 2280–2296.
38. Cowan, L.A., Talwar, S., Yang, A.S., Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics 2:1 (2010), 71–86.
39. Qin, T., Jelinek, J., Si, J., Shu, J., Issa, J.P., Mechanisms of resistance to 5-aza-2’-deoxycytidine in human cancer cell lines. Blood 113:3 (2009), 659–667.
40. Cortez, C.C., Jones, P.A., Chromatin, cancer and drug therapies. Mutat Res 647:1-2 (2008), 44–51.
41. Jones, P.A., Taylor, S.M., Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:1 (1980), 85–93.
42. Marquez, V., Eritja, R., Kelley, J.A., Vanbemmel, D., Christman, J., Potent inhibition of HhaI DNA methylase by the aglycon of 2-(1H)-pyrimidinone riboside (Zebularine) at the G(C)under-barGC recognition domain. J Mol Bio 323:1 (2002), 53–67.
43. Balch, C., Yan, P., Craft, T., et al. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Therapeut 4:10 (2005), 1505–1514.
44. Allfrey, V.G., Faulkner, R., Mirsky, A.E., Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci USA 51 (1964), 786–794.
45. Xhemalce, B., Dawson, M.A., Bannister, A.J., Histone modifications. Reviews in Cell Biology and Molecular Medicine, 2006, Wiley-VCH Verlag GmbH & Co. KGaA.
46. Oki, M., Aihara, H., Ito, T., Role of histone phosphorylation in chromatin dynamics and its implications in diseases. Sub-cellular Biochem 41 (2007), 319–336.
47. Ng, S.S., Yue, W.W., Oppermann, U., Klose, R.J., Dynamic protein methylation in chromatin biology. Cell Mol Life Sci – CMLS 66:3 (2009), 407–422.
48. Shi, Y., Lan, F., Matson, C., et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:7 (2004), 941–953.
49. Barski, A., Cuddapah, S., Cui, K., et al. High-resolution profiling of histone methylations in the human genome. Cell 129:4 (2007), 823–837.
50. Klauke, K., Radulovic, V., Broekhuis, M., et al. Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation. Nat Cell Biol 15:4 (2013), 353–362.
51. Cao, R., Tsukada, Y., Zhang, Y., Role of Bmi-1 and Ring1A in H2A ubiquitylation and hox gene silencing. Mol Cell 20:6 (2005), 845–854.
52. Eskeland, R., Leeb, M., Grimes, G.R., et al. Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. Mol Cell 38:3 (2010), 452–464.
53. Kondo, Y., Shen, L., Cheng, A.S., et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40:6 (2008), 741–750.
54. McCabe, M.T., Ott, H.M., Ganji, G., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492:7427 (2012), 108–112.
55. Huet, S., Xerri, L., Tesson, B., et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Blood Cancer J, 7(4), 2017, e555.
56. Gursoy-Yuzugullu, O., Carman, C., Serafim, R.B., Myronakis, M., Valente, V., Price, B.D., Epigenetic therapy with inhibitors of histone methylation suppresses DNA damage signaling and increases glioma cell radiosensitivity. Oncotarget 8:15 (2017), 24518–24532.
57. Williams, K., Christensen, J., Helin, K., DNA methylation: TET proteins-guardians of CpG islands?. EMBO Rep 13:1 (2011), 28–35.
58. Almeida, L.O., Neto, M.P.C., Sousa, L.O., Tannous, M.A., Curti, C., Leopoldino, A.M., SET oncoprotein accumulation regulates transcription through DNA demethylation and histone hypoacetylation. Oncotarget 8:16 (2017), 26802–26818.
59. Nam, S., Li, M., Choi, K., Balch, C., Kim, S., Nephew, K.P., MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological functions of microRNA expression. Nucleic Acids Res 37:suppl 2 (2009), W356–W362.
60. Musilova, K., Mraz, M., MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia 29:5 (2015), 1004–1017.
61. Varambally, S., Cao, Q., Mani, R.S., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (New York, NY) 322:5908 (2008), 1695–1699.
62. Friedman, J.M., Liang, G., Liu, C.C., et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 69:6 (2009), 2623–2629.
63. Zhu, H., Leung, S.W., Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies. Diabetologia 58:5 (2015), 900–911.
64. Erdogan, B., Facey, C., Qualtieri, J., et al. Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol 39:9 (2011), 915–926.e912.
65. Schiano, C., Vietri, M.T., Grimaldi, V., Picascia, A., De Pascale, M.R., Napoli, C., Epigenetic-related therapeutic challenges in cardiovascular disease. Trends Pharmacol Sci 36:4 (2015), 226–235.
66. Han, H., Wolff, E.M., Liang, G., Epigenetic alterations in bladder cancer and their potential clinical implications. Adv Urol, 2012, 2012, 11.
67. Juergens, R.A., Wrangle, J., Vendetti, F.P., et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 1:7 (2011), 598–607.
68. Pera, B., Tang, T., Marullo, R., et al. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clin Epigenet, 8(1), 2016, 79.
69. Clozel, T., Yang, S., Elstrom, R.L., et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov 3:9 (2013), 1002–1019.
70. Cameron, E.E., Bachman, K.E., Myohanen, S., Herman, J.G., Baylin, S.B., Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:1 (1999), 103–107.
71. Shen, H., Laird Peter, W., In epigenetic therapy, less is more. Cell Stem Cell 10:4 (2012), 353–354.
72. Kaminskas, E., Farrell, A., Abraham, S., et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11:10 (2005), 3604–3608.
73. Schwartsmann, G., Schunemann, H., Gorini, C.N., et al. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest N Drugs 18:1 (2000), 83–91.
74. Brown, R., Glasspool, R., Epigenetic modulation of resistance to chemotherapy?. Ann Oncol 18:9 (2007), 1429–1430.